Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?

ABSTRACT: In recent years, we have seen the development and approval for clinical use of an increasing number of therapeutic agents against actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC). Among them, selective inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies targeting the mesenchymal-epithelial transition (MET) receptor, have been studied in patients with advanced NSCLC with MET deregulation, primarily due to exon 14 skipping mutations or MET amplification. Some MET TKIs, including capmatinib and tepotinib, have proven to be highly effective in this molecularly defined subgroup of patients and are already approved for clinical use. Other similar agents are being tested in early-stage clinical trials with promising antitumo

SUBMITTER: Spagnolo CC 

PROVIDER: S-EPMC10299133 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature